Sleep-Administered ketamine/psychedelics : A streamlined strategy to address two challenges in research on ketamine and psychedelics
(2025) In European Psychiatry 68(1).- Abstract
The dissociative effects of ketamine and psychedelics might be associated with their rapid antidepressant properties, raising questions about whether these effects are necessary for their therapeutic action. Additionally, the distinct dissociative experiences often reported by patients in clinical trials may reveal whether they receive an active treatment or a placebo, potentially introducing bias into the results. In this viewpoint, we propose administering ketamine/psychedelics to patients during sleep, offering a novel approach to address and explore these challenges.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1cb1f22d-fdf1-4a66-8668-1ea2b093e413
- author
- Arjmand, Shokouh
; Lindström, Mats B.
LU
; Sellgren, Carl M. and Wegener, Gregers
- organization
- publishing date
- 2025-02-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- blinding, ketamine, mechanism of action, psychedelics, rapid-Acting antidepressants
- in
- European Psychiatry
- volume
- 68
- issue
- 1
- article number
- e29
- publisher
- Elsevier Masson SAS
- external identifiers
-
- scopus:85217469074
- pmid:39905718
- ISSN
- 0924-9338
- DOI
- 10.1192/j.eurpsy.2025.14
- language
- English
- LU publication?
- yes
- id
- 1cb1f22d-fdf1-4a66-8668-1ea2b093e413
- date added to LUP
- 2025-04-09 09:56:02
- date last changed
- 2025-07-30 18:32:44
@article{1cb1f22d-fdf1-4a66-8668-1ea2b093e413, abstract = {{<p>The dissociative effects of ketamine and psychedelics might be associated with their rapid antidepressant properties, raising questions about whether these effects are necessary for their therapeutic action. Additionally, the distinct dissociative experiences often reported by patients in clinical trials may reveal whether they receive an active treatment or a placebo, potentially introducing bias into the results. In this viewpoint, we propose administering ketamine/psychedelics to patients during sleep, offering a novel approach to address and explore these challenges.</p>}}, author = {{Arjmand, Shokouh and Lindström, Mats B. and Sellgren, Carl M. and Wegener, Gregers}}, issn = {{0924-9338}}, keywords = {{blinding; ketamine; mechanism of action; psychedelics; rapid-Acting antidepressants}}, language = {{eng}}, month = {{02}}, number = {{1}}, publisher = {{Elsevier Masson SAS}}, series = {{European Psychiatry}}, title = {{Sleep-Administered ketamine/psychedelics : A streamlined strategy to address two challenges in research on ketamine and psychedelics}}, url = {{http://dx.doi.org/10.1192/j.eurpsy.2025.14}}, doi = {{10.1192/j.eurpsy.2025.14}}, volume = {{68}}, year = {{2025}}, }